Ovarian Cancer Clinical Trial
Official title:
An International Field Study of the Reliability and Validity of a Disease-Specific Questionnaire Module (the QLQ-OV28) in Assessing the Quality of Life of Patients With Ovarian Cancer
RATIONALE: Quality-of-life assessment in patients undergoing cancer treatment may help
determine the intermediate- and long-term effects of treatment.
PURPOSE: This clinical trial studies the quality of life in patients with ovarian cancer.
OBJECTIVES: I. Evaluate the scale structure and reliability of the ovarian cancer specific
questionnaire module (EORTC QLQ-OV28) designed to be used in conjunction with the standard
nonspecific questionnaire (EORTC QLQ-C30) in patients with ovarian epithelial cancer. II.
Evaluate the psychometric properties of the revised scales (physical and role functioning;
global health status/QL) of the EORTC QLQ-C30 among ovarian cancer patients. III. Evaluate
the evidence for the validity of EORTC QLQ-OV28.
OUTLINE: This is a multicenter study. Patients are stratified according to prior therapy and
disease. Questionnaires are designed to be completed by patients themselves without help.
Patients complete the EORTC QLQ-C30, QLQ-OV28, and a debriefing questionnaire regarding time
to completion and patient's reaction to the quality of life questionnaires according to one
of the following schedules: Group 1: Patients complete the questionnaires once prior to the
start of the first course of chemotherapy, and again on the first day of the third course of
chemotherapy. Group 2: Patients complete the questionnaires once 1 to 8 weeks following
completion of the 6th course of chemotherapy and prior to any further anticancer therapy.
Group 3: Patients complete the questionnaires once at a routine follow-up clinic visit and
again at home within 3 days of the clinic visit. Group 4: Patients complete the
questionnaires once prior to the first course of chemotherapy and again on the first day of
the 3rd course of chemotherapy prior to administration OR at the first clinical review
following 2 courses of chemotherapy OR 2 months later for patients receiving continuous or
weekly chemotherapy. If they are unable to complete written questionnaires due to physical
limitations or illiteracy, or if they express a strong preference for oral administration,
patients in Groups 1, 2, and 4 may complete the questionnaires orally instead.
PROJECTED ACCRUAL: A minimum of 280 patients will be accrued for this study within 2 years.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
| Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
| Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
| Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
| Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
| Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
| Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |